Search Patents
  • USE OF INDOLE COMPOUNDS AS A COSMETIC
    Publication number: 20130045174
    Abstract: The invention relates to a compound of formula I wherein R1, R2 and R3 are identical or different and each is H or alkyl of 1-6 carbon atoms, R4 is H or methyl, R5 is phenyl or chlorophenyl, and/or physiologically acceptable salts thereof and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound.
    Type: Application
    Filed: October 22, 2012
    Publication date: February 21, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventor: Merck Patent Gesellschaft Mit Beschrankter Haftu
  • Polymorphs of losartan and the process for the preparation of form II of losartan
    Patent number: 5608075
    Abstract: Polymorphic forms of Losartan (Formula I) ##STR1## and a process for the preparation of Form II of Losartan. Losartan is known to be useful in the treatment of hypertension.
    Type: Grant
    Filed: January 12, 1995
    Date of Patent: March 4, 1997
    Assignees: Merck & Co., Inc., E. I. Du Pont de Nemours & Company, The DuPont Merck Pharmaceutical Company
    Inventors: Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • MAMMALIAN GENES; RELATED REAGENTS
    Publication number: 20130203060
    Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 8, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Merck Sharp & Dohme Corp.
  • Azetidine glycine transporter inhibitors
    Patent number: 7572792
    Abstract: The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: August 11, 2009
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Limited
    Inventors: Craig W Lindsley, David Hallett, Scott E. Wolkenberg
  • Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl
    Patent number: 6441002
    Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: are disclosed. The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 27, 2002
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Sophie Dorothee Clas, Louis S. Crocker, James A. McCauley, Ian Davies, Chad Dalton
  • Process for preparing peptide intermediates
    Patent number: 7262169
    Abstract: The present invention is directed to the improved synthesis of compounds of formula (I) an intermediate compound which is useful in the synthesis of the anticancer agents known as PSA conjugates.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: August 28, 2007
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Limited
    Inventors: Michael Stewart Ashwood, Brian Christopher Bishop, Ian Frank Cottrell, Khateeta Moneek Emerson, David Hands, Guo Jie Ho, Joseph Edward Lynch, Yao Jun Shi, Robert Darrin Wilson
  • CONDUCTING FORMULATION
    Publication number: 20130161594
    Abstract: The invention relates to novel formulations comprising an organic semiconductor (OSC) and a conductive additive, to their use as conducting inks for the preparation of organic electronic (OE) devices, especially organic photovoltaic (OPV) cells, to methods for preparing OE devices using the novel formulations, and to OE devices and OPV cells prepared from such methods and formulations.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 27, 2013
    Applicants: KONARKA TECHNOLOGIES, INC., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Merck Patent Gesellschaft mit Beschrankter Haftung, KONARKA TECHNOLOGIES, Inc.
  • Process for producing FK-506
    Patent number: 5116756
    Abstract: Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: January 28, 1991
    Date of Patent: May 26, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Francis Dumont, George M. Garrity, Isabel M. Fernandez, Teresa D. Matas
  • BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
    Publication number: 20130217695
    Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: March 20, 2013
    Publication date: August 22, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Merck Sharp & Dohme Corp.
  • RORgammaT inhibitors
    Patent number: 9603838
    Abstract: The present invention relates to compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 28, 2017
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor
    Patent number: 4582842
    Abstract: Novel 6H-dibenz[b,e] [1,4]oxathiepin derivatives of the formula I and Ia are employed in the treatment and control of allergic conditions such as allergic asthma.
    Type: Grant
    Filed: September 26, 1983
    Date of Patent: April 15, 1986
    Assignees: Merck & Co., Inc., Merck Frosst Canada
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney
  • Process for the Prepartion of an Orexin Receptor Antagonist
    Publication number: 20210309650
    Abstract: The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof.
    Type: Application
    Filed: July 16, 2015
    Publication date: October 7, 2021
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Ltd.
    Inventors: Carl A. Baxter, Edward Cleator, Faye Sheen, Shane W. Krska, Gavin Stewart, Neil Strotman, Debra J. Wallace, Timothy Wright
  • Process for the preparation of an orexin receptor antagonist
    Patent number: 8674093
    Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: March 18, 2014
    Assignees: Merck Canada Inc., Merck Sharp & Dohme Corp.
    Inventors: Louis-Charles Campeau, John Y. Chung, Danny Gauvreau, Melina Girardin-Rondeau, Gregory Hughes, Kevin M. Maloney, Christophe Mellon, Jeffrey C. Moore, Paul O'Shea, Stephane Ouellet
  • Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid
    Patent number: 4402979
    Abstract: This invention relates to ophthalmic preparations which include 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid or ophthalmologically acceptable salts thereof as the active entity for reducing or controlling inflammation of the eye.
    Type: Grant
    Filed: October 28, 1981
    Date of Patent: September 6, 1983
    Assignees: Merck & Co., Inc. & Laboratories, Merck, Sharp & Dohme-Chibret
    Inventors: Tsung-Ying Shen, Philippe Conquet, Jean-Claude Le Douarec
  • Polymorphic form of montelukast sodium
    Patent number: 7560559
    Abstract: The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium: acetonitrile solvates, which are intermediates in the formation of crystalline montelukast sodium.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: July 14, 2009
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Jun-Hong Chou, Michael B. Gentzler, James N. Michaels, Cynthia Bazin, Sophie-Dorothee Clas, Chad Dalton, Michael Guojie Wu
  • Microbial transformation products with antifungal properties
    Patent number: 5972994
    Abstract: Biotransformation products of a fermentation with Streptomyces sp., (Merck Culture Collection MA7165) ATCC No. 55946 are potent antifungal agents. These products may be useful in the treatment of diseases caused by fungal pathogens such as Candida sp. and Cryptococcus neoformans.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ali Shafiee, Guy H. Harris, Deborah L. Zink, Janet M. Sigmund, Mark J. Rosenbach, Suzanne Miller Mandala
  • Synthesis of methylthiophenyl hydroxyketones
    Patent number: 6281391
    Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 28, 2001
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski
  • CATHEPSIN CYSTEINE PROTEASE INHIBIORS
    Publication number: 20130035312
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: October 11, 2012
    Publication date: February 7, 2013
    Applicants: Axys Pharmaceuticals, Inc., Merck, Sharp & Dohme, Corp.
    Inventors: Merck, Sharp & Dohme, Corp., Axys Pharmaceuticals, Inc.
  • Stereoselective synthesis of a 4,4-disubstituted cyclohexanepropanoic acid
    Patent number: 7411088
    Abstract: There is provided stereoselective route to a compound of formula I: wherein R represents H or an alkali metal, Ar1 represents 4-chlorophenyl and Ar2 represents 2,5-difluorophenyl.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: August 12, 2008
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Ltd.
    Inventors: Karel Marie Joseph Brands, Sarah Elizabeth Brewer, Antony John Davies, Ulf H. Dolling, Deborah Camille Hammond, David Ross Lieberman, Jeremy Peter Scott
Narrow Results

Filter by US Classification